Category: Melanoma Stories
How Jaqueline’s Promise and Persistence Paid Off
5 March 2019 In Melanoma Stories
Melanoma wasn't supposed to happen to Jacqueline. Melanoma was supposed to be a disease that older, white women got, not 21-year-old African Americans. "People often think having more melanin makes them from developing melanoma. But they’re wrong,” Jacqueline says.
Unchartered Territory: When Should Patients Stop Immunotherapy?
For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? In the absence of definitive data – what does indirect data tell us?
From Health Scare to Transformative Change
Debra Black founded the Melanoma Research Alliance in 2007 after her own diagnosis with Stage II disease earlier that year. Since then, MRA has become the largest, non-profit funder of melanoma research worldwide.
Connecting the Dots: MRA’s 2017-2018 Annual Report
In our 2017/18 report, we are proud to showcase many key achievements from the past year. Check out the annual report to learn more about the research we’ve funded, the partnerships we’ve forged, the progress we’ve made and the donors who help to make it all possible.
For Kimberly, Clinical Trials Were a Leap of Faith
1 October 2018 In Melanoma Stories
Kimberly was just 19-years-old when she noticed the black “freckle” on her foot. But it wasn’t until she was 22-years-old and pregnant with her first child that her “freckle” became a cause for concern.
Ipilimumab Cured Dan Engel He’s Committed to Paying it Forward
Dan needed a miracle. At this point, he’d had six surgeries on his neck, endured radiation therapy, and been enrolled in five clinical trials. Dan’s miracle came in 2006 in the form of an experimental drug, ipilimumab or anti-CTLA4 antibody, that would later be named Yervoy. This drug would later become the first new FDA-approved melanoma treatment in 13 years.
Wiser & Stronger – Life after Metastatic Melanoma
For Derrick, it all started with headaches. For the first time in his life, this otherwise perfectly healthy father of two, knew something was wrong.
Uveal ‘Clusters’ in Auburn, AL and Huntersville, NC
When we talk about melanoma, it’s easy to forget that cutaneous – the most common variety that forms on the skin – isn’t the only game in town. Uveal represents about 5% of all melanomas diagnosed each year. So, when dozens of people from two towns in North Carolina and Alabama were diagnosed with the rare cancer alarm bells sounded.